Evidence map›Paper›PMID 42343346›Full record

ArticleVirology journal2026

oHSV-1-modulated m

Xiaoyang Qin, Yan Jia, Peiwen Wang, Hongwei Yang, Rui Wu, Fusheng Liu, Junwen Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaoyang Qin *Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Yan Jia *Department of Laboratory Medicine, Tianjin Hospital, Tianjin, China.
Peiwen Wang *Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Hongwei YangDepartment of Laboratory Medicine, Tianjin Hospital, Tianjin, China.
Rui WuBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Fusheng LiuBeijing Neurosurgical Institute, Capital Medical University, Beijing, China. liufusheng@ccmu.edu.cn.
Junwen ZhangBeijing Neurosurgical Institute, Capital Medical University, Beijing, China. jewzhang@hotmail.com.

Funding

National Natural Science Foundation of China No. 82503943Youth Innovation Fund of Beijing Neurosurgical Institute 2060354-24
6 · The paper itself

Abstract

backgroundOncolytic virus therapy is a highly promising approach for the treatment of glioblastoma (GBM). The RNA alteration N6-methyladenosine (m

methodsWe employed a new oncolytic herpes simplex virus type 1 (HSV-1), designated oHSV-1, which we had previously engineered. Mechanistic studies were performed to elucidate the involved pathways.

resultsWe demonstrate that oHSV-1 specifically downregulates the m

conclusionsThese findings reveal a novel epigenetic mechanism of oHSV-1-induced apoptosis and support the therapeutic potential of combining oHSV-1 with epigenetic inhibitors for GBM treatment.

Indexed as

AdenosineAlkB Homolog 5, RNA DemethylaseApoptosisGlioblastomaHerpesvirus 1, HumanOncolytic VirusesProtein-Arginine N-MethyltransferasesCell Line, TumorEpitranscriptomeHumansOncolytic VirotherapyRNA MethylationAdenosineALKBH5 protein, humanAlkB Homolog 5, RNA Demethylasecoactivator-associated arginine methyltransferase 1N-methyladenosineProtein-Arginine N-MethyltransferasesALKBH5ApoptosisCARM1GlioblastomaN6-methyladenosine (m6A)Oncolytic virus

Identifiers

PMID42343346
PMCPMC13625249

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.